Cutaneous T cell lymphoma

The Worldwide Photopheresis Products Industry is Expected to Reach $730.9 Million by 2027: Rise in Prevalence of Autoimmune Diseases Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Health, Science, Other Science, Research, Clinical Trials, Ansoff Matrix, SWOT, System, Autoimmune disease, USD, Hospital, Porter's five forces analysis, Risk, Cutaneous T cell lymphoma, Graft-versus-host disease, Growth, Impact, Investment, Competitive analysis, COVID-19, Emotion, Observation, Market development, Geography, Pharmaceutical industry, Retail, Risk management, Rail freight transport

The Global Photopheresis Products Market is estimated to be USD 452 Mn in 2022 and is expected to reach USD 730.93 Mn by 2027, growing at a CAGR of 10.09%.

Key Points: 
  • The Global Photopheresis Products Market is estimated to be USD 452 Mn in 2022 and is expected to reach USD 730.93 Mn by 2027, growing at a CAGR of 10.09%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Photopheresis Products Market stakeholders.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
  • By Therapeutic Area, the market is classified into Autoimmune Diseases, Cutaneous T-cell Lymphoma, Graft Versus Host Diseases, and Solid Organ Transplant Rejections.

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
NF-κB, Annual report, Security (finance), ASH, Memorial Sloan Kettering Cancer Center, COVID-19, IRF4, B-cell lymphoma, Disease, Safety, Biotechnology, Skin, Cutaneous T cell lymphoma, Boston, Boston Business Journal, Risk, Society, Lymphatic system, Therapy, MDM2, PDX, Immunomodulatory imide drug, CTCL, MYD88, Pathology, Apoptosis, Patient, Science, CDX, STAT3, DLBCL, Vaccine, Pharmaceutical industry, Black Majesty, Medicine, IRAK4

WATERTOWN, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that preclinical data from collaborations for its STAT3 and IRAKIMiD degraders was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 - 13, 2022 in New Orleans, Louisiana.

Key Points: 
  • The model was used to evaluate the therapeutic potential of one of Kymera’s potent and selective STAT3 heterobifunctional degraders for targeting this difficult-to-treat hematologic malignancy.
  • A single intravenous infusion of a STAT3 degrader led to substantial reduction in STAT3 levels in lymph node T cells, circulating T cells, and skin-resident T cells.
  • These data provide a rationale for selective STAT3 degradation as a therapeutic strategy for T cell malignancies such as CTCL that are associated with constitutive activation of STAT3 signaling.
  • Kymera’s lead STAT3 degrader, KT-333, is currently being evaluated in a Phase 1 clinical trial in liquid and solid tumors, including CTCL.

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Monday, December 12, 2022
Immunotherapy, Lymphoma, B-cell lymphoma, T helper 17 cell, Head, Cutaneous T cell lymphoma, Clinical trial, PD, Incidence, Partnership, Atopic dermatitis, Prevalence, SD, Neoplasm, Poster, Safety, ITK, Pharmacokinetics, TCL, Toxic epidermal necrolysis, Large-cell lung carcinoma, ASH, Exposition, Neck, CR, T-cell lymphoma, Patient, PTCL, Autoimmunity, Research, Plasma, Society, PR, Abdominal wall, PRS, Vaccine, Pharmaceutical industry, Palladium, T helper cell, Corvus, TH1

BURLINGAME, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced updated results from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, which demonstrated its anti-tumor activity in patients with T cell lymphoma (TCL) and its therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases. The data will be presented today in a poster at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 10 to 13, 2022.

Key Points: 
  • The data will be presented today in a poster at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 10 to 13, 2022.
  • Based on the clinical results to-date, we plan to advance CPI-818 into a global Phase 2 clinical trial in T cell lymphoma in mid-2023.
  • Accordingly, Corvus identified it as the optimal dose and additional patients are being enrolled in a 200 mg dose cohort of the clinical trial.
  • The Phase 1/1b clinical trial endpoints are safety, pharmacokinetics (PK), immunologic effects and tumor response.

Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit

Retrieved on: 
Thursday, November 3, 2022
Research, Public Relations, Investor Relations, Clinical Trials, Communications, Biotechnology, General Health, Health, Science, Oncology, Other Science, Technology, Cytokine, Private Securities Litigation Reform Act, Therapy, Risk, EDGAR, IL-9, Multi, Safety, MCI, Toxic shock syndrome, Hair loss, Trial of the century, Nasdaq, Boston Park Plaza, Degenerative disease, MCP, Inflammation, Itolizumab, Peptide, Forward-looking statement, Drug development, Cutaneous T cell lymphoma, Summit, Feedback, JAK, SEC, Autoimmunity, Patient, Alopecia areata, CTCL, Pharmaceutical industry, Vaccine

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 6th Annual Dermatology Drug Development Summit.

Key Points: 
  • Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 6th Annual Dermatology Drug Development Summit.
  • The presentation highlights Equilliums Multi-Cytokine Inhibitor EQ101 as a novel molecular compound to treat alopecia areata.
  • Responsible for the signaling of more than 50 cytokines, the JAK/STAT pathways have become key targets for drug development, with multiple JAK inhibitors approved over the last decade.
  • The presentation is available on the Multi-Cytokine tab of the Presentations page under the Technology section of the company website.

Micreos’ Alternative to Antibiotics Secures Next €25 Million

Retrieved on: 
Tuesday, October 25, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Time, CH, MRSA, Micreos, Salmonella, Olympiacos B.C. B Development Team, Cutaneous T cell lymphoma, Enzyme, Technology Center, Technology, NL, Rosacea, Discovery, Industry, Cheese, Atopic dermatitis, Bacteria, Skin, Lysin, Dermatitis, Bloodstream infections, USDA, Staphylococcus, Acne, FDA, Meat, Ulcer, Poultry, Pharmaceutical industry, Listeria, The Hague

Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of 25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.

Key Points: 
  • Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of 25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.
  • Over the past year Micreos separated its Pharmaceutical business from its Over the Counter Consumer Health business.
  • Micreos CEO Mark Offerhaus: With this restructuring we align business and market requirements, enabling each business to pursue its own growth strategy.
  • Micreos develops targeted antibacterial solutions based on endolysin- and phage technology as a sustainable alternative for antibiotics.

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

Retrieved on: 
Thursday, September 15, 2022
Adult, Lymph, Risk, STAT3, Therapy, Peripheral T-cell lymphoma not otherwise specified, Safety, COVID-19, Twitter, PTCL, FDA, CTCL, Entrepreneurship, Food, Lymphatic system, Blood, Skin, Peripheral, LinkedIn, Itch, Cutaneous T cell lymphoma, Degenerative disease, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, T-cell lymphoma, CEO, Annual report, Nasdaq, Diagnosis, Science, Boston Business Journal, NASDAQ, Aggressive lymphoma, Boston, Security (finance), Biotechnology, Rash, GLOBE, Medicine, Cancer, Lymphoma, Peripheral T-cell lymphoma, Pharmaceutical industry, Black Majesty

Deregulation of STAT3 signaling has been implicated in the pathogenesis of a variety of cancers, including CTCL.

Key Points: 
  • Deregulation of STAT3 signaling has been implicated in the pathogenesis of a variety of cancers, including CTCL.
  • KT-333 received orphan drug designation for the treatment of Peripheral T-cell Lymphoma ( PTCL ) earlier this year.
  • TheFDA'sOrphan Drug Designation program provides orphan status to drugs defined as those intended for the treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people inthe United States.
  • Orphan drug designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.

Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress

Retrieved on: 
Thursday, August 4, 2022
FDA, Liver, Jazz Pharmaceuticals, Intellectual property, U.S. Securities and Exchange Commission, Cell, Injection, CEO, Initiate, GLOBE, Neoplasm, Private Securities Litigation Reform Act, SEC, Therapeutic index, Toxicity, Infection, Society, Security (finance), Research, Liver disease, CTCL, CEPI, Patient, Lonza, Bladder cancer, Gene, Company, Cutaneous T cell lymphoma, Program, Partnership, Exosome, Safety, NASDAQ, Biology, Colorectal cancer, AAV, Medical imaging, Fine chemical, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported second quarter 2022 financial results and recent operational progress.

Key Points: 
  • During the second quarter we made strong progress supporting our approach and making advancements across our pipeline.
  • Total revenues for the quarter ended June 30, 2022, were $13.1 million, compared to $0.9 million for the same period in 2021.
  • Research and development expenses were $12.8 million for the quarter ended June 30, 2022, compared to $15.4 million for the same period in 2021.
  • As of June 30, 2022, Codiak had cash, cash equivalents, and marketable securities of approximately $41.8 million.

Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™

Retrieved on: 
Thursday, June 30, 2022
Patient, CTCL, GLOBE, Blood, Cancer, U.S. Securities and Exchange Commission, Overalls, Neoplasm, IND, Cohort, Webcast, Security (finance), PTGFRN, FDA, Injection, Engineering, Tropism, Pharmacology, Therapy, Stimulator of interferon genes, PDF, MIBC, Immunotherapy, Infection, Protein, Peptide, Bladder cancer, Cutaneous T cell lymphoma, Therapeutic index, Private Securities Litigation Reform Act, Squamous cell carcinoma, Nasdaq, Cell, Biology, Biomarker, Șaeș, Disease, Merkel-cell carcinoma, Plasma, Toxic leukoencephalopathy, Exosome, PD-L1, Toxicity, Tumor microenvironment, Safety, Physician, Pharmaceutical industry, Generic drug, Vaccine, Cmax

CAMBRIDGE, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced platform-validating clinical data from Phase 1 trials of exoSTINGTM and exoIL-12™ and plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety and tolerability profile, with no detectable systemic exposure of IL-12 and no treatment-related adverse events, which has not previously been reported by others with recombinant IL-12. The two patients with cutaneous T cell lymphoma (CTCL) who have been treated each received multiple (>20) injections of exoIL-12 and experienced tumor regressions in both injected and non-injected lesions, including a partial response in one patient. In the open-label Phase 1/2 clinical trial evaluating exoSTING as a single agent in patients with late-stage refractory solid tumors, data across all five dose cohorts showed repeat doses of exoSTING were well-tolerated, demonstrated tumor retention with no systemic exposure of the STING agonist, and in a subset of patients, tumor shrinkage was observed in injected and uninjected lesions.  

Key Points: 
  • We plan to initiate a Phase 2 study of exoSTING in bladder cancer and a Phase 2 study of exoIL-12 in an expanded group of tumor types in the first quarter of 2023.
  • The Phase 1 clinical trial was designed in two parts, with the data from the healthy volunteer portion of the study reported last year .
  • The data support advancing exoSTING into Phase 2 development, particularly in early-stage disease where combination with immunotherapy may lead to enhanced activity.
  • Codiak intends to focus development of exoIL-12 on tumors that have, in previous clinical testing, shown clinical responses to IL-12 used as a monotherapy.

Sensei Biotherapeutics Announces Executive Promotions

Retrieved on: 
Thursday, January 6, 2022
Tumor microenvironment, Therapy, Drug discovery, Pembrolizumab, PricewaterhouseCoopers, University of Washington Department of Bioengineering, University, Anatomical pathology, Growth, Yale College, Northwest Biotherapeutics, Company, Fred Hutchinson Cancer Research Center, Environment, Research, Patient, University of Massachusetts Medical School, Cancer, Brown University, Twitter, Squamous cell carcinoma, NASDAQ, Biomarker, LinkedIn, Merkel-cell carcinoma, Type 2, Philosophy, Intarcia Therapeutics, Vertex Pharmaceuticals, Merck, VISTA, Cystic fibrosis, GLOBE, Immunotherapy, CTCL, Industry, MCC, Cutaneous T cell lymphoma, Management, Sensei

Both Erin and Rob have made substantial contributions to Sensei, including critical roles in our initial public offering and pipeline expansion, respectively, said John Celebi, chief executive officer of Sensei Biotherapeutics.

Key Points: 
  • Both Erin and Rob have made substantial contributions to Sensei, including critical roles in our initial public offering and pipeline expansion, respectively, said John Celebi, chief executive officer of Sensei Biotherapeutics.
  • They have each built strong teams and helped Sensei navigate a high level of growth within a complex environment.
  • Their promotions reflect not only their accomplishments to this point, but our confidence in their respective abilities to help lead the Company into the future
    Erin Colgan joined Sensei Biotherapeutics in 2020 and has been responsible for all accounting, finance, and business functions.
  • Sensei Biotherapeutics is a biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer.

Micreos appoints Matt Regan as CEO of its Pharmaceutical business

Retrieved on: 
Thursday, October 14, 2021
Staphylococcus aureus, Salmonella, Inflammation, Technology, ETH, OTC, Growth, Atopic dermatitis, Acne, Dermatitis, Health, Staphylococcus, Cutaneous T cell lymphoma, Multimedia, Patient, Rosacea, AbbVie, Diabetes, Biotechnology, S. aureus, Bacteria, Commercial, CEO, Skin cancer, Pharmaceutical industry

THE HAGUE,Netherlands, Oct. 14, 2021 /PRNewswire/ --Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland.

Key Points: 
  • THE HAGUE,Netherlands, Oct. 14, 2021 /PRNewswire/ --Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland.
  • Following rapid growth, Micreos is preparing to spin-out its Pharmaceutical business into a separate company as per January 2022 to directly access the capital markets.
  • Its pharmaceutical lead compounds are XZ.700, which specifically kills Staphylococcus aureus, and SP.800, which kills all staphylococci.
  • Matt joins Micreos with extensive biopharmaceutical experience from almost 3 decades working with Global healthcare leaders including Abbott, Novo Nordisk, and AbbVie.